Single dose PK study on Patients [Design Issues]
Dear Ohlbe,
Thank you for responding. Drug is Olaparib and OGD recommends Two-way crossover Steady State PK study. One of our client wish to conduct single dose BE study as a conventional design without interrupting ongoing treatment of patient. Now whether its a feasible by taking appropriate measures of clinical safety?
Regards,
Pharma_88
Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Ohlbe]
Thank you for responding. Drug is Olaparib and OGD recommends Two-way crossover Steady State PK study. One of our client wish to conduct single dose BE study as a conventional design without interrupting ongoing treatment of patient. Now whether its a feasible by taking appropriate measures of clinical safety?
Regards,
Pharma_88
Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Ohlbe]
—
Regards,
Pharma_88
Regards,
Pharma_88
Complete thread:
- Single dose PK study on Patients Pharma_88 2024-05-15 05:37 [Design Issues]
- Single dose PK study on Patients Ohlbe 2024-05-15 09:39
- Single dose PK study on PatientsPharma_88 2024-05-17 10:06
- No, sorry Ohlbe 2024-05-17 13:45
- No, sorry Pharma_88 2024-05-20 06:50
- Deviating from a guidance Helmut 2024-05-20 07:57
- Deviating from a guidance Pharma_88 2024-05-21 08:32
- No, sorry Ohlbe 2024-05-21 12:41
- Deviating from a guidance Helmut 2024-05-20 07:57
- No, sorry Pharma_88 2024-05-20 06:50
- No, sorry Ohlbe 2024-05-17 13:45
- Single dose PK study on PatientsPharma_88 2024-05-17 10:06
- Single dose PK study on Patients Ohlbe 2024-05-15 09:39